8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$11M | 64.8% | -484.3% | -$9M | — | $6M |
| 2024 | $515000 | -$17M | -215.5% | -3349.7% | -$15M | — | $12M |
| 2023 | $11M | -$7M | 81.8% | -68.5% | -$4M | — | $27M |
| 2022 | $299000 | -$17M | -33.8% | -5718.1% | -$15M | — | $30M |
| 2021 | $16M | $237000 | 87.2% | 0.4% | $1M | $249000 | $13M |
| 2020 | $6M | -$6M | 51.1% | -91.2% | -$5M | $11000 | $3M |
| 2019 | $2M | -$11M | 18.9% | -329.2% | -$7M | $63000 | $4M |
| 2018 | $5M | -$6M | 66.9% | -84.7% | -$2M | — | $5M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Jun '25 | $179000 | -$3M | -3.9% | -1775.4% | — | — | $11M |
| Jun '24 | $249000 | -$4M | -115.3% | -1769.5% | — | — | $19M |
| Jun '23 | $10M | $6M | 94.0% | 55.7% | — | — | $22M |
| Jun '22 | $66000 | -$4M | 34.8% | -6340.9% | — | — | $36M |
| Jun '21 | $691000 | -$3M | 37.9% | -443.3% | — | — | $17M |
| Jun '20 | $823000 | -$2M | 9.1% | -232.4% | — | — | $4M |
| Jun '19 | $606000 | -$1M | 23.6% | -290.6% | — | — | — |
How the market has priced CLGN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, CollPlant Biotechnologies Ltd's revenue has declined 17.3% per year. These are computed facts, not advice.
As of FY2025, CollPlant Biotechnologies Ltd reported — of total debt against $6M of cash.
In FY2025, gross margin was 64.8%, operating margin -484.3%, and net margin -484.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.